Gilead part­ner Ar­cus earns an­a­lyst­s' plau­dits for ear­ly pan­cre­at­ic can­cer da­ta that 'ex­ceed­ed ex­pec­ta­tion­s'

Ar­cus’ small mol­e­cule CD73 in­hibitor for pan­cre­at­ic can­cer got a stand­ing ova­tion from an­a­lysts who said pre­lim­i­nary da­ta “ex­ceed­ed ex­pec­ta­tions”— mak­ing waves in a field that’s seen lit­tle progress in sev­er­al years and prov­ing the can­di­date could be worth the hun­dreds of mil­lions Gilead pro­vid­ed up­front in a deal that in­clud­ed more than a bil­lion dol­lars for opt-in rights and mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER